U.S., Dec. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07270874) titled 'LIVER AKI: A Randomized, Open-label Trial to Evaluate the Efficacy of Intravenous Human Albumin Administration Versus Saline Solution in Patients With Decompensated Cirrhosis and AKI 1B or Grater.' on Nov. 14.
Brief Summary: This is a phase IV, unicentric, open-label. Patients eligible for this study will be patients with AKI 1B or greater and decompensated cirrhosis from the hospital participating in the study
Study Start Date: Jan., 2026
Study Type: INTERVENTIONAL
Condition:
Decompensated Cirrhosis
AKI - Acute Kidney Injury
Intervention:
DRUG: Saline solution (NaCl 0.9%)
Saline solution (NaCl 0.9%) 500 ml every 24 hours, adm...